https://scholars.lib.ntu.edu.tw/handle/123456789/581610
標題: | Orbital exenteration: A 20-year experience from a tertiary center in Taiwan | 作者: | Wang W.-Y. SHU-LANG LIAO YI-HSUAN WEI |
關鍵字: | Exenteration; Lymphovascular invasion; Melanoma; Orbit; Sebaceous gland carcinoma | 公開日期: | 2021 | 出版社: | Elsevier B.V. | 卷: | 120 | 期: | 7 | 起(迄)頁: | 1493-1499 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Purpose: To describe the prognostic factors and survival outcomes in patients who underwent orbital exenteration surgery at a tertiary center over a 20-year period. Methods: This institutional retrospective study reviewed all patients who underwent orbital exenteration between January 1999 and January 2019 at Department of Ophthalmology, National Taiwan University Hospital. Patient demographics, tumor site, histopathology, status of surgical margins, additional resection, local recurrence, metastases, survival, and treatment data were recorded. Log-rank tests were used to verify the difference in survival curves among various potential prognostic factors. Results: Thirty patients (27 with malignancy, 1 with hybrid neurofibroma/schwannoma, and 2 with mucormycosis) were included. Malignant melanoma (n = 11) and sebaceous gland carcinoma (n = 8) were the most common indications for exenteration. Survival rates were 83% at 1 year, 42% at 3 years, and 33% at 5 years. Among patients with malignancies, 71% patients had clear margins after exenteration. All the incidences of local recurrence developed in the first 2 years postoperatively. Postoperative survival was significantly related to lymphovascular invasion (p = 0.018), but was independent from surgical margins, presence of metastasis, local recurrence, or perineural invasion. Conclusion: We found worse prognosis with positive lymphovascular invasion. Although not significant, malignant melanoma showed poorer survival times compared to sebaceous gland carcinoma. Close follow-up, especially in the first 2 years after orbital exenteration, is crucial to identify disease recurrence. ? 2020 Formosan Medical Association |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85095995371&doi=10.1016%2fj.jfma.2020.10.030&partnerID=40&md5=301f7ae9355194bfc1b120b40ee63e5c https://scholars.lib.ntu.edu.tw/handle/123456789/581610 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2020.10.030 | SDG/關鍵字: | antifungal agent; antineoplastic agent; mitomycin; adenoid cystic carcinoma; adult; aged; antifungal therapy; Article; cancer prognosis; cancer recurrence; cancer survival; clinical article; clinical outcome; demography; drug megadose; female; histopathology; human; lymph vessel metastasis; male; melanoma; middle aged; mucormycosis; neurilemoma; neurofibroma; orbital exenteration; perineural invasion; retrospective study; sebaceous carcinoma; squamous cell carcinoma; surgical margin; survival rate; Taiwan; epidemiology; orbital exenteration; skin tumor; tumor recurrence; Humans; Neoplasm Recurrence, Local; Orbit Evisceration; Retrospective Studies; Skin Neoplasms; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。